**Form 7**

**MONTHLY PROGRESS REPORT**

**April 2017**

Name of CSE Issuer: **Veritas Pharma Inc.** (the “Issuer”)

Trading Symbol: **VRT**

Number of Outstanding Listed **38,714,590 common shares and 23,043,115 common shares**

Securities: **reserved for issuance**

Date: **May 1, 2017**

**Report on Business**

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

On April 18, 2017, the Company announced that CEO and President, Dr. Lui Franciosi will present at The Planet Microcap Showcase 2017 alongside a panel of executives active in the development of cannabis related products. The Showcase takes place April 26-28, 2017 at Planet Hollywood Resort & Casino in Las Vegas, Nevada. www.PlanetMicroCapShowcase.com. It brings together the most promising companies and the top dealmakers in MicroCap Finance for three days of company presentations, one-on-one meetings, and networking. The attendees include executives, investors, financial professionals and industry leaders. Dr. Franciosi will also be attending the Canadian Cannabis Business Conference from May 23 to 26 in Toronto, www.CanadianInstitute.com/Canadian-Cannabis-Business-Conference The Conference will examine the different aspects of the emerging medical and recreational cannabis industry in Canada. The range of topics include: law and regulations, public health and safety, finance and banking, public and government relations, as well as marketing and advertising. He will also participate in workshops on navigating the license application process; marketing and branding cannabis; PR and GR for cannabis; and leveraging data analysis.

On April 21, 2017, the Company announced that, further to its December 21, 2015 and October 5, 2016 news releases, it has paid the final installment for its acquisition of 80% of the issued and outstanding shares in Cannevert Therapeutics Ltd. ("CTL” or “Cannevert"), and the Company will enter into a second amending agreement (the “Second Amending Agreement”) with respect to the existing share purchase agreement with Cannevert.

Pursuant to the Second Amending Agreement, the Company and Cannevert will engage an independent business valuator within 90 days to report on the value of Cannevert. The Company will provide a future update once a valuator has been appointed.

**Provide a general overview and discussion of the activities of management.**

**See Item 1 above.**

1. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**None.**

1. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**None.**

1. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**None.**

1. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**See 1 above.**

1. Describe any acquisitions by the Issuer or dispositions of the Issuer’s assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**See 1 above**

1. Describe the acquisition of new customers or loss of customers.

**None.**

1. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

**None.**

1. Report on any employee hiring, terminations or lay-offs with details of anticipated length of lay-offs.

**None**

1. Report on any labour disputes and resolutions of those disputes if applicable.

**None.**

1. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**None.**

1. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

**None**

1. Provide details of any securities issued and options or warrants granted.

**Issued 200,000 shares of common stock through the exercise of stock options raising $100,000.**

1. Provide details of any loans to or by Related Persons.

**None**

1. Provide details of any changes in directors, officers or committee members.

**None**

1. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.

**None.**

**Certificate Of Compliance**

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CSE that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CSE Requirements (as defined in CSE Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated:  **June 19, 2017**

David Alexander

Name of Director or Senior Officer

Signature

Chief Financial Officer

Official Capacity

|  |  |  |
| --- | --- | --- |
| ***Issuer Details*** |  |  |
| Name of Issuer:**Veritas Pharma Inc.** | For Month End**April, 2017** | Date of Report: YYYYMMDD **2017/05/01** |
| Issuer Address: **101 – 2386 East Mall,** **University of British Columbia,**  |  |
| City/Province/Postal Code: **Vancouver, BC V6T 1Z3** | Issuer Fax No.: **778.262.0120** | Issuer Telephone No. **778.968.6260** |
| Contact Name:**David Alexander** | Contact Position:**CFO** | Contact Telephone No. **778-772-8184**  |
| Contact Email Address:**info@veritas.com** | Web Site Address:[**www.veritas.com**](http://www.veritas.com) |